1,429 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
CELG Celgene Corporation $87.23 $61.35B Uptrend
Article Searches
Top Research Reports for Amazon, Verizon & AbbVie http://www.zacks.com/research-daily/207529/top-research-reports-for-amazon-verizon-abbvie?cid=CS-ZC-FT-207529 Jan 23, 2019 - Top Research Reports for Amazon, Verizon & AbbVie
CELG or VRTX: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/349030/celg-or-vrtx-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-349030 Jan 23, 2019 - CELG vs. VRTX: Which Stock Is the Better Value Option?
Federal shutdown starting to hurt San Diego's science, biomedical research industries http://www.sandiegouniontribune.com/business/sd-me-shutdown-science-20190122-story.html Jan 23, 2019 -

The partial shutdown of the federal government is starting to affect key projects in San Diego’s huge science and biomedical research industries, including the approval of new drugs and a landmark study of California’s marine environment.

“We have at least $25 million in delayed research project...

What's in Store for Bristol-Myers (BMY) in Q4 Earnings? http://www.zacks.com/stock/news/348553/whats-in-store-for-bristol-myers-bmy-in-q4-earnings?cid=CS-ZC-FT-348553 Jan 21, 2019 - Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks https://seekingalpha.com/article/4234239-week-san-francisco-2019-great-year-healthcare-stocks?source=feed_all_articles Jan 18, 2019 -
This sluggish market may call for a 'low and slow' portfolio https://www.cnbc.com/2019/01/18/this-sluggish-market-may-call-for-a-low-and-slow-portfolio-ab-bernstein-says.html Jan 18, 2019 - The secret to outperforming the market in a downturn is to buy stocks that have "low and slow" characteristics — lower multiples and higher returns relative to the S&P 500 and trades that are less crowded, according to AB Bernstein.
Celgene teams up with Kyn Therapeutics in cancer https://seekingalpha.com/news/3424191-celgene-teams-kyn-therapeutics-cancer?source=feed_news_all Jan 18, 2019 -
Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA http://www.zacks.com/stock/news/348232/roches-sbla-for-tecentriq-abraxane-combo-accepted-by-fda?cid=CS-ZC-FT-348232 Jan 17, 2019 - Roche's (RHHBY) sBLA for the label expansion of Tecentriq in combination with Abraxane for the initial treatment of NSCLC has been accepted by the FDA.
1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet) https://www.fool.com/investing/2019/01/17/1-chart-that-shows-why-celgene-has-been-bought-out.aspx?source=iedfolrf0000001 Jan 17, 2019 - Revenue growth is key.
Celgene: Great Opportunities For Option Investors https://seekingalpha.com/article/4234039-celgene-great-opportunities-option-investors?source=feed_sector_healthcare Jan 17, 2019 - To me, special situations give investors the opportunity to enhance their total return.With little downside risk potential and annualized returns of more than 30%, Celgene shares are worth looking at

Pages: 123456...143

Page 1>

Related Companies

Name Exchange Price Mkt Cap
AGN Allergan plc. NYSE $184.29 $62.56B
SHPG Shire plc NASDAQ $176.25 $46.08B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
ZTS Zoetis Inc. NYSE $88.3 $42.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $386.665 $41.78B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Celgene
CELG - Google Finance https://www.google.com/finance?q=CELG Industry related info and international coverage Summary News
CELG - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=CELG Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options